This Article Full Text Full Text (PDF) All Versions of this Article: 38/3/1076    most recent 01.STR.0000258075.58283.8fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Álvarez-Sabín, J. Articles by Montaner, J. Search for Related Content PubMed PubMed Citation Articles by Álvarez-Sabín, J. Articles by Montaner, J. Related Collections Cerebrovascular disease/stroke Other Treatment Acute Cerebral Infarction Anticoagulants Thrombolysis Other Stroke Treatment - Medical Other Stroke Treatment - Surgical

(Stroke. 2007;38:1076.)
© 2007 American Heart Association, Inc.

Research Reports

Prior Statin Use May Be Associated With Improved Stroke Outcome After Tissue Plasminogen Activator

José Álvarez-Sabín, MD, PhD; Rafael Huertas, MD; Manolo Quintana; Marta Rubiera, MD; Pilar Delgado, MD; Marc Ribó, MD, PhD; Carlos A. Molina, MD, PhD Joan Montaner, MD, PhD

From the Neurovascular Research Laboratory, Neurovascular Unit, Neurology Department, Hospital Universitario Vall d’Hebron, Barcelona, Spain.

Correspondence to Joan Montaner, MD, PhD, Laboratorio de Investigación Neurovascular, Unidad Neurovascular (Servicio de Neurología), Institut de Recerca, Hospital Universitari Vall d’Hebron, Pg Vall d’Hebrón 119-129, 08035 Barcelona, Spain. E-mail 31862jmv{at}comb.es

Background and Purpose— Statins may exert some neuroprotection, because use before stroke onset has been related to better outcome and reduced mortality. The purpose of this study was to evaluate whether patients who receive tissue plasminogen activator have better outcome when statins were taken before stroke.

Methods— We evaluated 145 patients with a stroke involving the middle cerebral artery (who received tissue plasminogen activator treatment (<3 hours).

Results— Fifty-eight patients (40%) became functionally independent at 3 months. Factors associated with good outcome were age (68 versus 74.4 years, P<0.001), baseline National Institutes of Health Stroke Scale score (13 versus 18, P<0.001), and proximal middle cerebral artery occlusion (56.1% versus 84.3%, P<0.001). Statins were the only drug taken before stroke that conditioned neurologic outcome. In fact, among patients who were functionally independent, 27.3% were under statins at the time of the index stroke as compared with 13.6% among the group of patients who were dependent or dead by the end of the study period (P=0.046). A logistic regression model identified baseline National Institutes of Health Stroke Scale score <15 (OR: 5.8, 95% CI: 2.05 to 16.36, P=0.001), age <70 years (OR: 2.93, 95% CI: 1.13 to 7.59, P=0.027), and previous treatment with statins (OR: 5.26, 95% CI: 1.48 to 18.72, P=0.027) as independent predictors of good functional outcome.

Conclusions— Patients under statins at the moment of stroke who received thrombolytics had an improved neurologic outcome.

Key Words: neuroprotection • statin • stroke • thrombolysis • t-PA

This article has been cited by other articles:

				N. Meier, K. Nedeltchev, C. Brekenfeld, A. Galimanis, U. Fischer, O. Findling, L. Remonda, G. Schroth, H. P. Mattle, and M. Arnold Prior Statin Use, Intracranial Hemorrhage, and Outcome After Intra-Arterial Thrombolysis for Acute Ischemic Stroke Stroke, May 1, 2009; 40(5): 1729 - 1737. [Abstract] [Full Text] [PDF]

				M. J. Alberts, R. A. Felberg, L. R. Guterman, S. R. Levine, and for Writing Group 4 Atherosclerotic Peripheral Vascular Disease Symposium II: Stroke Intervention: State of the Art Circulation, December 16, 2008; 118(25): 2845 - 2851. [Full Text] [PDF]

				J. R. Romero, J. Morris, and A. Pikula Review: Stroke prevention: modifying risk factors Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 287 - 303. [Abstract] [PDF]

				M. Rodriguez-Yanez, J. Agulla, R. Rodriguez-Gonzalez, T. Sobrino, and J. Castillo Review: Statins and stroke Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 157 - 166. [Abstract] [PDF]

				R. C. Bucelli, E. A. Gonsiorek, W.-Y. Kim, D. Bruun, R. A. Rabin, D. Higgins, and P. J. Lein Statins Decrease Expression of the Proinflammatory Neuropeptides Calcitonin Gene-Related Peptide and Substance P in Sensory Neurons J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1172 - 1180. [Abstract] [Full Text] [PDF]

				J. Montaner Cholesterol Measured Before Stroke Thrombolysis Is Not Associated With Tissue Plasminogen Activator-Related Hemorrhagic Transformation Stroke, January 1, 2008; 39(1): e6 - e6. [Full Text] [PDF]

				L. Zhang, Z. G. Zhang, X. S. Liu, A. Hozeska-Solgot, and M. Chopp The PI3K/Akt Pathway Mediates the Neuroprotective Effect of Atorvastatin in Extending Thrombolytic Therapy After Embolic Stroke in the Rat Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2470 - 2475. [Abstract] [Full Text] [PDF]